Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 2,000,000 target

Helix Research Network

Helix

NCT06057181

Recruiting 20,000 target

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Freenome Holdings

NCT06122077

Recruiting Phase 3 11,000 target

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Boehringer Ingelheim

NCT06531824

Recruiting 5,000 target

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

DexCom

NCT06483945

Recruiting 5,000 target

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

HistoSonics

NCT06486454

Recruiting 4,500 target

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Michael J. Fox Foundation for Parkinson's Research

NCT04477785

Recruiting NA 2,996 target

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Stanford University

NCT05297734

Recruiting NA 2,529 target

Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response

VA Office of Research and Development

NCT04142177

Recruiting 2,400 target

Prospective Study of oncRNA Stratification of Cancer by Size and Stage

Exai Bio

NCT05833360

Recruiting 2,100 target

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Mayo Clinic

NCT04363684

Recruiting 2,000 target

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

Abbott Medical Devices

NCT03876054

Recruiting NA 2,000 target

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

Stratpharma

NCT05953090

Recruiting Phase 3 1,800 target

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera

NCT07284875

Recruiting Phase 3 1,700 target

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera

NCT07284901

Recruiting Phase 4 1,335 target

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Mayo Clinic

NCT06972056

Recruiting Phase 3 1,200 target

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera

NCT07284979

Recruiting 1,200 target

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

GAP Innovations, PBC

NCT06584357

Recruiting NA 1,100 target

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

Population Health Research Institute

NCT04743765

Recruiting Phase 3 1,100 target

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

AstraZeneca

NCT07218809

Recruiting Phase 3 1,023 target

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Merck Sharp & Dohme

NCT07216703

Recruiting NA 1,000 target

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

DiaSorin Molecular

NCT06672692

Recruiting Phase 3 1,000 target

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Eli Lilly and Company

NCT07412756

Recruiting Phase 3 1,000 target

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Bristol-Myers Squibb

NCT06561386

Recruiting 1,000 target

A Post-Market Domestic (US) and International Data Collection to Assess the Truliant Knee System

Exactech

NCT05653102

Recruiting 1,000 target

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

Cleo Diagnostics

NCT06566716

Recruiting Phase 2 982 target

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Pfizer

NCT06989437

Recruiting Phase 3 975 target

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Merck Sharp & Dohme

NCT07216482

Recruiting Phase 3 974 target

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Eli Lilly and Company

NCT06948422

Recruiting Phase 2 960 target

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

GlaxoSmithKline

NCT07204964

Recruiting Phase 1 930 target

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Relay Therapeutics

NCT05216432

Recruiting 900 target

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Ascendis Pharma Endocrinology Division A/S

NCT05820672

Recruiting Phase 3 900 target

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Hoffmann-La Roche

NCT07174310

Recruiting 900 target

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Tempus AI

NCT07211178

Recruiting Phase 1 862 target

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

DualityBio

NCT05914116

Recruiting Phase 3 860 target

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

AstraZeneca

NCT05211895

Recruiting Phase 2 854 target

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

AbbVie

NCT07005102

Recruiting Phase 3 850 target

Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

HALEON

NCT07215767

Recruiting NA 825 target

Randomized Trial of Healthy Family Foundations

Penn State University

NCT05630482

Recruiting 820 target

MDR - PMCF Study for Taperloc Complete Stems

Zimmer Biomet

NCT04028687

Recruiting Phase 3 800 target

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Eli Lilly and Company

NCT07369011

Recruiting Phase 1 796 target

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio

NCT05150691

Recruiting Phase 3 783 target

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

AbbVie

NCT06575192

Recruiting Phase 3 750 target

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

Hoffmann-La Roche

NCT06094010

Recruiting Phase 3 723 target

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Pfizer

NCT06641466

Recruiting Phase 3 686 target

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Merck Sharp & Dohme

NCT06459180

Recruiting Phase 3 614 target

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Merck Sharp & Dohme

NCT06170788

Recruiting Phase 2 600 target

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

PPD Development

NCT06703073

Recruiting Phase 2 596 target

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Bristol-Myers Squibb

NCT07100080

Recruiting Phase 3 550 target

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Shanghai Henlius Biotech

NCT06532006

Recruiting 550 target

FSL2 Post Approval Study for Pediatric and Young Adults Patients

Abbott Diabetes Care

NCT04959552

Recruiting 550 target

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Tempus AI

NCT07154823

Recruiting NA 545 target

Hydrus® Microstent New Enrollment Post-Approval Study

Alcon Research

NCT04553523

Recruiting Phase 3 540 target

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Novartis Pharmaceuticals

NCT04557462

Recruiting Phase 3 540 target

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Tenax Therapeutics

NCT07288398

Recruiting Phase 2 531 target

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Eli Lilly and Company

NCT07219173

Recruiting Phase 2 501 target

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics

NCT04442022

Recruiting 500 target

Multicenter Outcome Registry of AnaLgesic Effect of SCS(MORALES) Registry Protocol

Cardio Surgical Partners

NCT04548375

Recruiting Phase 3 500 target

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Sermonix Pharmaceuticals

NCT05696626

Recruiting 500 target

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Urotronic

NCT06560476

Recruiting 500 target

Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

Luminopia

NCT06429280

Recruiting 500 target

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

RedDress

NCT04699305

Recruiting 500 target

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Ascendis Pharma Endocrinology Division A/S

NCT05775523

Recruiting Phase 1 500 target

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Amgen

NCT06333951

Recruiting NA 500 target

Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief

HALEON

NCT07300540

Recruiting Phase 3 500 target

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

Vanda Pharmaceuticals

NCT07221578

Recruiting Phase 3 500 target

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Vanda Pharmaceuticals

NCT06830044

Recruiting NA 496 target

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

VIVEX Biologics

NCT06778447

Recruiting Phase 3 487 target

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Eli Lilly and Company

NCT06948435

Recruiting Phase 3 487 target

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Eli Lilly and Company

NCT06952530

Recruiting Phase 3 480 target

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

BioNTech SE

NCT06340568

Recruiting Phase 3 477 target

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Merck Sharp & Dohme

NCT06997497

Recruiting Phase 3 462 target

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Novartis Pharmaceuticals

NCT05126277

Recruiting 450 target

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

AbbVie

NCT06107426

Recruiting 450 target

The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using an Artificial Intelligence Image Analysis Tool (MagentaTM) Increases the Usable Blastocyst Yield and Subsequent Pregnancy in Patients Undergoing IVF

Ovation Fertility

NCT06521372

Recruiting Phase 2 436 target

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Upstream Bio

NCT06966479

Recruiting Phase 3 416 target

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Boehringer Ingelheim

NCT06151574

Recruiting Phase 2 410 target

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences

NCT06295731

Recruiting Phase 3 400 target

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Boehringer Ingelheim

NCT07195695

Recruiting Phase 2 400 target

An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

Ageless Biotech

NCT06485843

Recruiting Phase 3 400 target

Randomized Withdrawal Study in Patients With Schizophrenia

Vanda Pharmaceuticals

NCT06961968

Recruiting Phase 2 393 target

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

GlaxoSmithKline

NCT06613698

Recruiting 375 target

A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers

HALEON

NCT07337109

Recruiting Phase 2 360 target

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Vicore Pharma AB

NCT06588686

Recruiting Phase 3 351 target

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

BeOne Medicines

NCT07043400

Recruiting Phase 1 350 target

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Amgen

NCT06360354

Recruiting Phase 3 340 target

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Merck Sharp & Dohme

NCT06079879

Recruiting Phase 2 324 target

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

ONL Therapeutics

NCT06659445

Recruiting NA 324 target

Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort

Novozymes A/S

NCT07163637

Recruiting Phase 2 320 target

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

AstraZeneca

NCT07276581

Recruiting Phase 1 319 target

A Study of XMT-1660 in Participants With Solid Tumors

Mersana Therapeutics

NCT05377996

Recruiting Phase 3 312 target

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

University of Maryland, Baltimore

NCT05615844

Recruiting 300 target

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

United Therapeutics

NCT05776225

Recruiting Phase 3 300 target

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Merck Sharp & Dohme

NCT06456346

Recruiting Phase 2 300 target

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Eli Lilly and Company

NCT06817356

Recruiting Phase 2 300 target

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Draig Therapeutics

NCT07300969

Recruiting Phase 2 300 target

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Boehringer Ingelheim

NCT06962839

Recruiting Phase 2 300 target

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

MapLight Therapeutics

NCT06887192

Recruiting NA 300 target

Desara ® One Single Incision Sling 522 Study

Caldera Medical

NCT04772131

Recruiting NA 300 target

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

Laminate Medical Technologies

NCT06516653

Recruiting Phase 2 290 target

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Merck Sharp & Dohme

NCT05139017

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →